OBJECTIVE: To assess whether weight cycling has adverse effects on blood lipids or blood pressure. DESIGN: Cohort study, six years of follow-up, comparing net change in blood lipids and blood pressure among weight cyclers and non-cyclers. SUBJECTS: Men (n 4353), age 35 ± 57 y, at high risk for heart disease because of smoking, high blood pressure, and elevated cholesterol concentration in the Multiple Risk Factor Intervention Trial (MRFIT) Ð a 22-site, multi-center collaborative primary prevention trial conducted in the US, 1973 ± 1983. MEASUREMENTS: A weight cycle was de®ned as loss and regain of at least 5% of mean weight. Outcome measures were changes from baseline to year six in total serum cholesterol, high density lipoprotein cholesterol (HDL), the ratio of total cholesterol to HDL, and diastolic blood pressure. ANALYSIS: Analysis of covariance models were developed, with number of weight cycles as the predictor variable. The hypothesis was that men who weight cycled would experience less improvement in blood lipids and blood pressure than those who did not cycle. Adjustments were made for net weight change and other factors affecting each outcome. RESULTS: Men who weight cycled did not have the predicted smaller improvements in total cholesterol, HDL, the ratio of total cholesterol to HDL, or diastolic blood pressure, compared with noncyclers. CONCLUSION: An adverse effect of weight cycling on blood pressure or blood lipids was not found. The excess mortality previously reported among weight cyclers in this population can probably not be attributed to effects on these CVD risk factors.
Introduction
Some health professionals question whether weight loss, per se, is an appropriate recommendation for all overweight individuals. Although weight loss improves health risk factors in the short run, 1,2 the vast majority of people who lose weight regain it, 3, 4 with associated worsening of health risk measures. 1, 5 A clinical issue of utmost importance is whether it is better to have lost and regained than never to have lost at all.
Controversy over this question has been fueled by publication of weight cycling studies involving eleven large cohorts. 6 ± 16 Cycling has been associated with increased mortality in eight of the populations, 8 ± 15 and with increased cardiovascular disease (CVD) or CVD mortality in six of the populations. 8,10,11,13 ± 16 However, serious methodological limitations identi®ed in each of the studies 17 ± 19 render the proposed link between weight cycling and mortality tenuous. Furthermore, to establish causality in the relationship between weight cycling and increased mortality, some credible mechanism must be identi®ed which could link weight cycling to increased risk of death.
Research that could identify a causal mechanism is sparse. CVD risk factors are prime candidates for mediators of increased mortality, but evidence for a detrimental effect of weight cycling on several CVD risk factor is inconsistent. Decreased glucose tolerance or increased incidence of diabetes mellitus was found among cycling Baltimore males, 6 Gothenburg females, 11 and Iowa women, 16 but not in Gothenburg males, 11 Connecticut women, 20 or obese adults in Pittsburgh, 21 Minnesota 21 or Estonia. 22 Higher waist to hip ratios were found among 87 Connecticut women with a history of weight cycling, 23 but no increases in waist-to-hip ratio (WHR) or visceral fat were seen in other weight cyclers. 6,24 ± 26 Blood presure was found to be elevated among cyclers in one small clinical study, 27 but neither blood pressure nor blood lipids were found to be elevated among cycling Baltimore males, 6 California residents, 28 or several smaller clinical populations. 20, 21, 24, 29, 30 The present study addresses whether weight cycling could be related mechanistically to increased mortality and increased CVD by examining the impact of weight cycling on blood lipid concentrations and blood pressure levels Ð in a very large population of men in whom weight cycling has been associated with increased mortality. 8 We hypothesized that men who experienced weight cycling over the 6-year course of the Multiple Risk Factor Intervention Trial (MRFIT) would realize less favorable improvements in the CVD risk factors total cholesterol concentration, HDL, the ratio of total cholesterol to HDL, and diastolic blood pressure, compared with men who did not weight cycle.
Methods

Study sample
The MRFIT data were obtained from public use tapes made available by the National Heart Lung and Blood Institute. The MRFIT data set was considered appropriate because higher mortality had been reported previously in weight cyclers from this population, 8 and because the data set included extensive documentation of weight, blood lipids, and blood pressure.
The MRFIT primary prevention trial, described in detail elsewhere, 31 included men age 35 ± 57 y, at high risk for heart disease because of elevated cholesterol, elevated blood pressure, or smoking, but without evidence of existing heart disease. After screening over 370 000 men from 1973 ± 1976, 12 866 meeting the inclusion criteria were randomly assigned to either the Special Intervention (SI) group or the Usual Care (UC) group. Men in the SI group were subsequently seen at least three times a year for six to seven years for intensive intervention on their CVD risk factors. Men in the UC group were referred to their usual sources of health care, but were brought in for annual health examinations for the same six-to seven-year period.
Exclusions
Men were excluded from the MRFIT for the following reasons: evidence of heart disease, blood cholesterol higher than 350 mgadl, use of medication for diabetes, dietary prescriptions incompatible with the MRFIT dietary protocol, excessive alcohol intake, refusal to consider stopping smoking, and weight greater than 50% above desirable weight. 31 For the current data analyses, additional exclusions were applied. To assure precision in quanti®cation of weight cycles, all of the 6438 men in the UC group, for whom weight was measured only at one-year intervals, were excluded, leaving 6428 SI group members, with weight documented every four months over a 6-year period. Subjects missing more than three of the 19 possible weight measurements or absent at the year six anniversary visit (n 1496) were dropped. Subjects who developed medical conditions over the course of the trial which would profoundly affect weight Ð cancer (n 235) and hyper-or hypothyroidism (n 36) Ð were eliminated from analysis. Subjects who reported unexplained weight loss at any annual medical examination were assumed to have cancer and were dropped. The 4661 participants retained were on average one year older, had higher cholesterol, HDL, and blood pressure, and were less likely to be smokers than those dropped, but did not differ with respect to weight or ratio of total cholesterol to HDL (Table 1) .
For analyses of changes in blood lipids, men who developed conditions expected to affect cholesterol after the MRFIT began Ð diabetes (n 366) or liver diseases (n 44) Ð were excluded, leaving 4251 subjects. For analyses of changes in blood pressure, men who developed conditions likely to affect blood pressure Ð renal disease (n 15), angina (n 292) and primary aldosteronism (n 1) Ð were excluded, leaving 4353 subjects.
Most data were collected during baseline screening and annual medical examinations, where extensive information about medical conditions, drug use, dietary history, physical activity levels and tobacco use were recorded. Weight, blood pressure, total serum cholesterol, and recent smoking history were documented every four months. 31 Subjects recruited later in the study did not undergo data collection after their sixth annual medical examination. Therefore, data collected at the sixth annual medical examination were considered to be the`®nal' mesurements for the purpose of this study. All weight measurements were checked for possible recording errors. A weight was suspected of being infeasible if that weight represented a change greater than 15% of body weight in one 4-month interval, and was more than 1.96 standard deviations above or below the subject's mean weight over the course of the trial. For each of the 107 weights meeting these criteria, the pattern of weight changes over the intervention period was also examined. Ninety-®ve weights were judged to be infeasible and were rede®ned as missing. After infeasible weights were eliminated, subjects who were missing three or more weights were excluded, and the remaining missing weights were replaced by the mean of the previous and subsequent weight.
Outcome variables
The outcome variables de®ned for this research were changes from baseline to year six in total serum cholesterol, plasma HDL, the ratio of total serum cholesterol to plasma HDL and diastolic blood pressure. Baseline and year six blood lipid concentrations were based on single blood samples collected while the subject was in the fasting state. 32 Seated diastolic blood pressure was de®ned as the Korotkoff ®fth-phase reading taken with a random-zero sphygmomanometer. 33 The value for baseline blood pressure was the average of four measurements Ð two at the second screening visit, and two at the third screening visit. The value for the year six blood pressure was the average of two measurements taken at the year six annual examination. 33 
Predictor variables
The predictor variables were measures of weight cycling. The primary measure of weight cycling was the number of weight cycles, where a weight cycle was de®ned as a loss and subsequent regain (or gain and subsequent loss) of at lest ®ve percent of the subject's mean weight over the course of the trial. (The SAS program used to count weight cycles is available from the authors.) With measurements at 4-month intervals, a single weight cycle could span a minimum of eight months to a maximum of six years. The decision to use a ®ve percent weight change to de®ne a cycle was based on the ®nding by Blair et al 8 that, in the MRFIT population, men who had undergone at least one ®ve percent weight cycle had an increased risk for all-cause mortality compared with stable-weight subjects. Because number of weight cycles does not re¯ect the magnitude of the weight changes, the standard error of the estimate of the regression of each subject's weight on time (s.e.e.) was also calculated.
Other variables
The following factors with potential for affecting outcomes were quanti®ed and included in statistical models where they were statistically associated with the outcome of interest.
Nutrition. Mean nutrient intakes over the three consecutive years for which 24-h dietary recalls were available (years one, two, and three) were calculated for each subject. If more than one of the three dietary recalls were missing, the mean values for all nutrients were de®ned as missing. Nutrition factors were added to a model only if they were signi®cantly correlated with the outcome. Included were alcohol, caffeine, calcium, cholesterol, per cent of calories as fat, the ratio of polyunsaturated to saturated fat, vitamin E, water-soluble ®ber.
Smoking. Subjects were classi®ed by smoking status during the MRFIT trial, using serum thiocyanate levels to verify claims of non-smoking. 34 A non smoker was one who, at baseline and at each annual visit, reported being a non-smoker and, in addition, had a serum thiocyanate level lower than 100 micromoles per liter. A continuous smoker was one who, at each visit, either reported being a smoker or was found to have a serum thiocyanate level of 100 micromoles per liter or more. An intermittent smoker was veri®ed to be a non-smoker on at least one visit but not at all visits. The mean number of cigarettes smoked per day as reported at each 4-month visit was also calculated.
Physical activity. Average minutes per day of leisure time physical activity (LTPA) were used, based on data collected at the ®rst annual visit with the Minnesota questionnaire. 35 For subjects whose total minutes of LTPA were coded as exceeding 8 h per day, LTPA was re-coded as missing data. Physical ®tness level at baseline was documented as exercise duration, de®ned as the number of minutes a subject was able to continue a submaximal graded exercise test.
Drugs. Medications were taken into account by categorizing subjects as to use or non-use of (a) antihypertensive drugs during the sixth year of intervention (used by 89% of SI men at some point during the trial), (b) the diuretics chlorthalidone and hydrothiazide Ð which had a side effect of raising total serum cholesterol Ð during the ®fth and sixth year of intervention (almost half of the SI subjects were taking one or the other of these drugs at some point during the study) and (c) cholesterol-lowering drugs during the ®fth and sixth year of intervention (used by four percent of subjects over the course of the trial).
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Variables related to weight change. Baseline weight, trend in weight (the slope of the regression of weight on time), net weight change from baseline to year six, and weight changes over the ®nal four months and the ®nal 12 months of intervention were documented. Three net weight change groups were de®ned Ð`loss' (5 percent or more),`gain' (5 percent or more), and`no change' (change of less than 5 percent).
Statistical tests
Statistical analysis was done using SAS (SAS System for Microsoft Windows, releases 6.10 and 6.12, SAS Institute Inc., Cary, North Carolina). The sample size was large enough to detect the following differences in outcomes between cyclers and non-cyclers at the alpha 0.05 mgadl for total cholesterol, 0.73 mgadl for HDL, 0.12 for the ratio of total cholesterol to HDL, and 0.76 mm Hg for blood pressure. Mean changes in lipids and blood pressure were calculated in four groups of men Ð those with a) no cycles, b) one cycle, c) two cycles, and d) three or more cycles. All potentially confounding variables signi®cantly associated with each outcome were then accounted for in analysis of covariance models. To control for the powerful effects of medications used in the MRFIT to control blood pressure and cholesterol, the same analysis of covariance models were repeated, excluding men who had taken during year ®ve or six of the trial any antihypertensive drug, any diuretic known to increase blood cholesterol levels or any cholesterol-lowering drug.
Because net weight change from baseline to year six was found to be more highly correlated with changes in blood lipids and blood pressure than any other variable, the multiple variable models were repeated separately for each of the three net weight change groups Ð loss, gain and no change. Additionally, net weight change was included as a covariate in all models. Trend in weight was also highly correlated with changes in risk factors, but because of its high correlation with net weight change was not included as a covariate.
Race did not contribute signi®cantly to any model, and there were no signi®cant interactions between race and weight cycling measures, so the 340 African American subjects (7 percent of the unexcluded population) and 146 subjects with other ethnic designations (3 percent) were combined with the White subjects in all reported analyses.
Additional analyses
Blair et al 8 found that the heaviest MRFIT participants did not experience the increased mortality with weight cycling that was observed among leaner men. To rule out the possibility that weight cycling may be affecting risk factors differently for heavy men, models were repeated separately for each tertile of baseline body mass index (BMI). Because smoking status has affected CVD risk factors and has interacted with measures of weight cycling, 14, 29, 36 models were also repeated separately for non-smokers, continuous smokers, and intermittent smokers.
To rule out the possibility that a threshold effect was being missed, 37 (a) all models were repeated with the predictor re-calculated as number of larger 10% weight cycles and (b) all models were repeated, substituting tertile of s.e.e. for number of weight cycles.
Results
Baseline and other characteristics of the study population At baseline (Table 2) , MRFIT subjects were middleaged and overweight, with high total cholesterol concentrations, low HDL concentrations, high ratios of total cholesterol to HDL, and moderately elevated diastolic blood pressure. Weight cyclers were somewhat younger and heavier than non-cyclers, but differed little with respect to cardiovascular risk factors. Table 3 shows mean values for pertinent weight change, nutrition, exercise, smoking, and medication use characteristics. Weight cyclers and non-cyclers did not differ with respect to mean weight over the trial, but cyclers lost more weight Ð both over the course of the trial, and during the last 4 months of intervention. Some cyclers had greater caffeine intakes than non-cyclers, and cyclers were heavier smokers than non-cyclers.
Weight cycling patterns
Twenty percent of subjects were non-cyclers, 53% experienced one cycle, 22% experienced two cycles, and ®ve percent experienced three or more cycles over the six-year period of this study. Table 4 shows patterns of weight cycling by net weight change and by baseline BMI. Weight cycling occurred to a similar extent whether men experienced a net weight loss or weight gain, with the exception that a higher proportion of weight gainers were non-cyclers. The number of weight cycles was fairly consistent across BMI groups, although the heaviest men experienced more weight cycles. Similarly, when the magnitude of weight variability was measured by s.e.e., the leanest men exhibited the least weight variability and the heaviest men exhibited the most weight variability.
(Data not shown.)
Results of data analyses
In general, weight cyclers did not show the predicted pattern of smaller improvements in cardiovascular risk factors than non-cyclers (Table 5 ). These results were unchanged when models were adjusted for all potentially confounding variables signi®cantly correlated with change in each outcome ( Table 5 ). The same results were obtained when individuals using medications with powerful effects on the outcomes Signi®cantly different from non-cyclers, P`0.05, Dunnett's 2-tailed t-test *s.e.e., the standard error of the estimate for the regression of each subject's weight on time; P:S ratio, ratio of polyunsaturated to saturated fat; LTPA, leisure time physical activity. a Based on subjects retained for blood lipid analyses (n 4251). Subjects were excluded for missing more than three 4-month interval weights, being absent at the year six annual examination, cancer, thyroid disease, diabetes, liver disease. BMI body mass index.
Weight cycling and CVD risk factors KA Petersmarck et al were excluded (Table 5) , and when men who gained weight, lost weight or experienced minimal weight change were considered separately (data not shown). Substituting tertile of s.e.e. for number of weight cycles in each model did not change the results (data not shown). Men with three or more weight cycles experienced signi®cantly different changes in some outcomes from non-cyclers; that is, smaller improvement in blood pressure and Ð unexpectedly Ð greater adjusted mean improvements in total cholesterol and HDL ratio. However, consistent dose-response relationships were not observed between the degree of weight cycling and the degree of improvement or decline in risk factors.
In comparing heavy vs lean men, Table 6 shows that seven of the 36 subsets of cycling men experienced signi®cantly greater improvements in risk factors than non-cyclers, while two subsets experienced smaller improvements. No consistent patterns of differing response by heavy men compared to lighter men were observed. In comparisons of smokers vs non-smokers, no signi®cant differences in outcomes were observed between any subset of cyclers vs noncyclers (data not shown).
Discussion
This research was prompted by the observation that weight cycling has been associated with increased mortality and CVD. 8 ± 16 We attempted to ®ll a serious gap in the study of weight cycling Ð namely, the absence of a demonstrated mechanism whereby weight cycling could be heightening mortality risk. Since increased CVD or increased CVD mortality has been identi®ed among weight cyclers, 8,10,11,13 ± 16 we looked for progressive worsening of cardiovascular risk factors with successive numbers of weight cycles. Our focus on intermediate outcomes measured immediately at the end of the observation period eliminates the in¯uence of uncontrollable factors that in¯uence Signi®cantly different from non-cyclers, P`0.05, Dunnett's 2-tailed t-test. c Signi®cantly different from non-cyclers, P`0.05, unpaired 2-tailed t-test. Means were adjusted for baseline total cholesterol, baseline weight, net weight change, number of cigarettes per day, vitamin E intake, calcium intake, cholesterol intake, water-soluble ®ber intake, the ratio of polyunsaturated to saturated fat, and total minutes of leisure time physical activity. For adjusted means, only subjects without missing data for all covariates were included. e Means were adjusted for baseline HDL, baseline weight, net weight change, number of cigarettes per day, vitamin E intake, alcohol intake, caffeine intake, cholesterol intake, per cent of calories as fat, and total minutes of leisure time physical activity. For adjusted means, only subjects with complete data for all coveriates were included. f Means were adjusted for baseline ratio of total cholesterol to HDL, baseline weight, net weight change, number of cigarettes per day, age, vitamin E intake, alcohol intake, caffeine intake, water-soluble ®ber intake, and the ratio of polyunsaturated to saturated fats. For adjusted means, only subjects with complete data for all coveriates were included. g Means were adjusted for baseline blood pressure, baseline weight, net weight change, number of cigarettes per day, vitamin E intake, weight change in the ®nal four months, alcohol intake, caffeine intake, calcium intake, cholesterol intake, percent of calories from fat, ratio of polyunsaturated to saturated fats, and exercise duration at baseline. For adjusted means, only subjects with complete data for all coveriates were included. h Subjects were excluded who, during years ®ve or six of intervention, took cholesterol-lowering drugs, or antihypertensives known to raise blood cholesterol levels (chlorthalidone, or hydrothiazide). l Subjects were excluded who, during year six of intervention, took antihypertensive drugs. *s.e., standard error Weight cycling and CVD risk factors KA Petersmarck et al the more remote endpoint of mortality. Had our hypothesis been correct, weight cyclers would have been less responsive to the MRFIT interventions to improve CVD risk factors. The results of these data analyses provided no support for our hypothesis.
The absence of detrimental effects of weight cycling on blood lipids or blood pressure is consistent with two population-based cohort studies 6, 28 and several smaller clinical studies addressing this issue, 20, 21, 24, 29, 30 but inconsistent with one small clinical study of blood pressure and weight cycling. 27 The ®nding that men with three or more weight cycles had signi®cantly better adjusted mean improvements in total serum cholesterol and in HDL ratio was unexpected. Could weight cycling somehow be construed as have a positive effect on these cardiovascular risk factors? Given the absence of a dose ± response improvement in risk factors with increasing weight cycles, and given the fact that weight cyclers experienced increased mortality in this population, it would seem unlikely that cycling confers a bene®t. The authors speculate that the improvements seen in these risk factors could have been related to the average weight loss of 1.9% of body weight experienced by the group of men with the most weight cycles during the four months prior to their ®nal blood lipid measurement.
The present study has a number of strengths which lend credibility to its ®ndings. The data were collected prospectively on a large population, with state-of-theart quality control procedures in place. Factors known to affect cardiovascular risk factors were accounted for in the data analyses. The documentation of weight is more complete than in other studies of weight cycling. Our documentation of weight variability was unique in that both the number of weight cycles and the amplitude of weight change were taken into account.
It is unlikely that the lack of association we found between weight cycling and worsening of risk factor levels was an artifact caused by the choice of analytic methods. Stepwise multiple regression models developed for each outcome yielded results that were completely consistent with the analysis of covariance results reported here. Our use of several different methods for describing weight cycles and two different statistical approaches lends additional credibility to the ®ndings.
It would have been ideal if we had been able to use the same exclusions and the same de®nition of weight cycling as were used by Blair et al 8 when they showed increased mortality among weight cyclers in this MRFIT population. However, since our intent was to identify a mechanism to explain the increased mortality, different approaches were needed. For example, we excluded subjects with conditions likely to exert drastic short-term effects on blood pressure and blood lipids Ð exclusions which were not necessary in a study of mortality.
Blair et al 8 used as the primary measure of weight cycling the standard deviation of up to seven weights 17 ± 19,38 Additionally, we made the decision to exclude all members of the Usual Care group. This was considered necessary because we were working toward establishing causality, so we needed to discern a dose-response effect of number of weight cycles on CVD risk factors if one existed. The seven annual weights available for the UC group allowed identi®-cation of a maximum of three weight cycles, whereas the 19 weights available for the SI group would permit identi®cation of up to nine cycles. In fact, when we counted the number of weight cycles in members of the SI group based ®rst on all 19 available weights and then again based on only their seven annual weights, we found that 40% of subjects were misclassi®ed as non-cyclers when only the seven annual weights were used. Thus, the weight cycling members of the MRFIT population we studied overlapped but were not identical to the MRFIT weight cyclers found to have increased mortality by Blair et al. 8 While our measures of weight cycling are more precise than those used in other weight cycling studies, there are limitations. First, there is no indicator of the duration of each weight cycle. For example, a loss and regain of 20 pounds within a period of eight months was indistinguishable from an identical weight loss and gain that occurred over a six-year period. Second, there is no control for the time lag between weight change and the measurement of change in outcome. The detrimental effect of weight regain on blood pressure found in weight cycling rats by Ernsberger et al 39 was observed only in the period immediately after weight regain. It is possible that spikes in blood pressure occurred immediately following periods of weight regain which were not detectable in this analysis. Third, there is no differentiation between cycles characterized by initial weight loss followed by regain and cycles that begin with a weight gain followed by a loss.
Whether weight cycles were voluntary or due to illness is not addressed in many studies. Weight loss was part of the MRFIT intervention for the 84% of SI men who met the study protocol's criteria for encouragement of weight loss, 32 at some point during the trial. Given intensive intervention for weight loss on so many of the men, it highly likely that voluntary weight loss with some amount of weight rebound was extremely common in this population. However, the MRFIT data set does not include variables that could clearly label each weight loss episode as voluntary or involuntary. Despite our elimination of subjects who reported unexplained weight loss at annual medical examinations, cancer or thyroid disease, it is likely that some weight changes due to physical or mental illness contributed to the weight cycling observed.
The results of this study cannot be generalized to as great a degree as desired. The population studied consisted only of men at high risk of heart disease who agreed to participate in the extensive intervention of the MRFIT. No conclusions can be drawn about the effect of weight cycling in women. There was little ethnic diversity among the population. Given the high prevalence of hypertension in the African American community, inability to generalize to African Americans is an important limitation of the study.
The results may not be generalizable to a population that is not undergoing intensive intervention on the CVD risk factors that are being studied Ð blood pressure and blood lipids. It is possible that any effect of weight cycling on the risk factors in question was simply overshadowed by the effects of the medical intervention. The authors do not consider this possibility to a¯aw in the study, however, since current clinical practice for controlling CVD risk factors would typically involve simultaneous use of drugs and weight loss. If weight cycling is detrimental to men undergoing pharmacologic treatment for risk factors, the medical provider community should know it. Furthermore, in the analyses where we controlled for the use of cholesterol-lowering drugs, diuretics, and anti-hypertensive drugs, we still were not able to document any detrimental effect of weight cycling.
The question remains Ð if weight cycling is causing increased mortality, by what mechanism could this be occurring? Most speculation as to possible mechanisms for excess mortality with weight cycling revolves around the weight loss phase of the weight cycle. The rapid, extensive weight loss caused by the liquid protein products used in the 1970s was associated with atrophy of cardiac tissue. 40 Food restriction in rats was shown to mobilize potentially toxic hexachlorobenzene from fat stores. 41 Phinney suggested that weight loss may be associated with increase in some unrecognized risk factor for CVD, such as changes in platelet function, increases in concentrations of arachidonic acid, or depletion of omega-3 fatty acid reserves. 42 Measures of immune function have shown detrimental changes with weight loss. 43 There have been suggestions that the weight gain phase could explain increased mortality with weight cycling. Keyes et al 44 speculated that irreversible atherogenesis occurs during periods of weight gain which is not offset by bene®ts incurred during weight loss. Cutter 45 conjectured that, if people who are heavier are more likely to weight cycle, the increased mortality associated with weight cycling could be the result of increased risk incurred while weight was elevated.
An aspect of weight cycling research which merits attention is the relationship among psychological status, stress, weight cycling, and mortality. Individuals with a history of weight cycling have been found to have decreased perceptions of health and well-being 46 and to show more signs of psychological pathology than those without such a history, independent of weight, 47 although this ®nding is not universal. 48 ± 50 Socially stressed primates exhibit accelerated atherogenesis. 51 
Conclusion
The hypothesis that men who weight cycled would experience less improvement in blood lipids and blood pressure than men who did not cycle was not supported. If weight cycling caused the increased mortality risk in the MRFIT Special Intervention Group previously reported by Blair et al, 8 it does not appear that the mechanism for the increased mortality was via effects on total cholesterol, HDL, the ratio of total cholesterol to HDL or diastolic blood pressure. While this ®nding is important for Caucasian middle-aged males at high risk for heart disease who are taking measures to reduce their risk factors, it cannot be generalized to younger men, women or minorities.
